- Home
- GIPR vs QNTM Comparison
GIPR vs QNTM Comparison
Compare GIPR & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIPR
- QNTM
- Stock Information
- Founded
- GIPR 2015
- QNTM 1998
- Country
- GIPR United States
- QNTM Canada
- Employees
- GIPR N/A
- QNTM N/A
- Industry
- GIPR Real Estate Investment Trusts
- QNTM
- Sector
- GIPR Real Estate
- QNTM
- Exchange
- GIPR Nasdaq
- QNTM NYSE
- Market Cap
- GIPR 9.7M
- QNTM 9.1M
- IPO Year
- GIPR 2021
- QNTM N/A
- Fundamental
- Price
- GIPR $1.77
- QNTM $3.42
- Analyst Decision
- GIPR Hold
- QNTM
- Analyst Count
- GIPR 1
- QNTM 0
- Target Price
- GIPR N/A
- QNTM N/A
- AVG Volume (30 Days)
- GIPR 27.7K
- QNTM 223.5K
- Earning Date
- GIPR 11-15-2024
- QNTM 01-28-2025
- Dividend Yield
- GIPR 11.02%
- QNTM N/A
- EPS Growth
- GIPR N/A
- QNTM N/A
- EPS
- GIPR N/A
- QNTM N/A
- Revenue
- GIPR $10,215,225.00
- QNTM N/A
- Revenue This Year
- GIPR N/A
- QNTM N/A
- Revenue Next Year
- GIPR $1.14
- QNTM N/A
- P/E Ratio
- GIPR N/A
- QNTM N/A
- Revenue Growth
- GIPR 72.92
- QNTM N/A
- 52 Week Low
- GIPR $1.50
- QNTM $2.70
- 52 Week High
- GIPR $4.64
- QNTM $70.85
- Technical
- Relative Strength Index (RSI)
- GIPR 48.69
- QNTM 41.28
- Support Level
- GIPR $1.66
- QNTM $3.20
- Resistance Level
- GIPR $1.78
- QNTM $3.55
- Average True Range (ATR)
- GIPR 0.09
- QNTM 0.43
- MACD
- GIPR -0.00
- QNTM -0.00
- Stochastic Oscillator
- GIPR 59.64
- QNTM 14.97
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in major markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.